CARDINAL HEALTH INC(CAH)— Stock Profile, AI Score & Financials
Consumer Staples · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
CARDINAL HEALTH INC (CAH) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores CAH at 62.4/100 on a 32-signal composite quality model, placing it at rank #712 of 2,961 stocks — the top 25% of the AI-ranked universe. CAH scores in the top quartile across revenue scale (99.5), earnings quality (83.1), institutional flow (78.1). Areas of concern include free cash flow (33.2) and profitability (36.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2026), CARDINAL HEALTH INC reports quarterly revenue of $254.2B, net income of $1.7B, an operating margin of 1.0%. Top institutional holders of CAH by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. CAH trades on the NYSE exchange and files with the SEC under CIK 721371. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CARDINAL HEALTH INC directly from SEC EDGAR.
AI Quality Score
62.4/100
AI Rank
#712
Revenue
$254.2B
Net Income
$1.7B
Free Cash Flow
$4.5B
Operating Margin
1.0%
CAH key financials by period
CARDINAL HEALTH INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$254.2B
$1.7B
1.0%
FY 2025
10-K
$222.6B
$1.6B
1.0%
FY 2024
10-K
$226.8B
$852.0M
0.5%
FY 2023
10-K
$205.0B
$330.0M
0.4%
FY 2022
10-K
$181.3B
$-938.0M
-0.3%
FY 2021
10-K
$162.5B
$611.0M
0.3%
Institutions holding CAH
Institutional investors reporting a position in CARDINAL HEALTH INC on SEC Form 13F.
AI-extracted from the 10-K filed 2026-08-11 — FY2026 (year ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Cardinal Health revenue reached $254.2B (+14% YoY) driven by branded and specialty pharma growth; non-GAAP operating earnings grew 30% to $3.6B, though a $184M Navista & ION goodwill impairment and tariff headwinds tempered GAAP results.
Biggest Revenue Drivers
Pharmaceutical and Specialty Solutions$234.8B+15% YoY
Branded and specialty pharmaceutical sales growth from existing and new customers, plus MSO platform acquisitions.
Global Medical Products and Distribution$12.7B+1% YoY
Cardinal Health brand growth offset by lower distribution volumes and IEEPA tariff refund customer repayments.
Biggest Revenue Drivers
Total revenue: $254.2B+14% YoY
Pharmaceutical and Specialty Solutions$234.8B+15% YoY
Branded and specialty pharmaceutical sales growth from existing and new customers, plus MSO platform acquisitions.
Global Medical Products and Distribution$12.7B+1% YoY
Cardinal Health brand growth offset by lower distribution volumes and IEEPA tariff refund customer repayments.
Other$6.8B+26% YoY
Growth across at-Home Solutions including ADS acquisition, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
Largest Expense Items
Cost of products sold$244.5B+14% YoY
Increased due to factors affecting revenue changes and gross margin performance.
Distribution, selling, general, and administrative expenses$6.1B+14% YoY
Increased primarily due to acquisitions of MSO platforms and ADS.
Amortization and other acquisition-related costs$469M+1% YoY
Amortization of acquisition-related intangible assets ($361M) and transaction/integration costs ($108M).
Margins: Gross margin increased 20% to $9.8B with a 17 basis point expansion driven by MSO acquisitions, increased branded and specialty pharma contributions, and strong generic program performance. However, margin rate benefited from higher-margin MSO businesses, partially offset by unfavorable product mix shifts from increased branded pharmaceutical distribution.
Watch Items from the Filing
CVS Health concentration: 28% of FY2026 revenue and 22% of gross receivables at June 30, 2026; loss would significantly impact operations.
Navista & ION goodwill impairment: $184M charge in Q3 FY2026 reflects reduced earnings expectations and increased discount rates; carrying value $909M remaining goodwill after impairment creates sensitivity to further declines.
Tariff exposure: ~$200M paid in IEEPA tariffs since Feb 2025 (primarily GMPD); $200M receivable recorded for expected government refunds; additional tariffs under other legal authorities continue to impact segment profit.
Five largest customers represent 43% of revenue; two largest GPO relationships (Vizient, Premier) represent 29% of revenue; customer concentration risk could materially impact results.
MSO acquisition integration: $1.9B Solaris Health acquisition completed Nov 2025 (post-period); integration risks and synergy realization remain, particularly given prior $184M impairment.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
